Curated news and analysis on clinical trials, drug approvals, and medical research.
Ultragenyx Pharmaceutical confronts multiple shareholder class action lawsuits over Phase III trial disclosures while reporting positive UX111 gene therapy data and implementing a 10% workforce reduction.
FLASH radiotherapy delivers therapeutic radiation doses in fractions of a second at rates exceeding 40 Gy per second, potentially reducing normal tissue damage while maintaining tumor control through altered oxygen dynamics.
Japan's Ministry of Health, Labour and Welfare granted Orphan Drug designation to Dyne Therapeutics' investigational treatment zeleciment-basivarsen for myotonic muscular dystrophy type 1, adding to existing designations in the U.S. and Europe.
Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.
Moderna posted Q4 2025 revenue of $678 million, beating analyst estimates despite a 29.8% year-over-year decline. The company reduced operating expenses by 31% while facing FDA refusal to file its flu vaccine application.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
Newron Pharmaceuticals has secured up to €38 million in milestone-based financing from European and Asian investors to advance its Phase III ENIGMA-TRS program evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia.
A phase 1 clinical trial demonstrates that mRNA-1283, a next-generation COVID-19 vaccine encoding receptor-binding and N-terminal domains of the spike protein, induces durable T cell immunity at a 10 µg dose comparable to the standard 100 µg mRNA-1273 vaccine.
NYU Langone Health researchers discover pancreatic cancer cells toggle between rapid growth and chemotherapy resistance based on their proximity to extracellular matrix fibers, complicating single-drug treatment approaches.
The U.S. Food and Drug Administration has approved an Investigational New Drug application for FRF-001, a viral gene therapy for FOXG1 syndrome developed at the University at Buffalo. The first-in-human trial will be independently sponsored by the FOXG1 Research Foundation.
The FDA approved an oral version of Wegovy in December 2025, providing a pill alternative to injections. Clinical trials showed comparable effectiveness between oral and injectable forms of semaglutide for weight loss.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
Generative AI is evolving from pilot projects to a foundational tool in life sciences, driving an estimated $60 billion to $110 billion in annual economic impact while accelerating drug discovery, reducing clinical trial timelines, and improving operational efficiency across the pharmaceutical sector.
The UK government is offering £20 million in grants through Innovate UK to develop cutting-edge medicines, medical technologies and digital tools to tackle drug and alcohol addiction, which causes around 15,000 deaths annually and costs England an estimated £47 billion each year.
Weight-loss drugs like Ozempic and Wegovy are creating visible facial changes in celebrities while scams targeting consumers surge nationwide. Multiple public figures have disclosed using GLP-1 medications, with some experiencing significant side effects.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
Rare Disease Day on February 28, 2026 highlights challenges in developing treatments for conditions with small patient populations. AI-driven digital twins and data-driven approaches are emerging as practical tools to overcome traditional trial constraints.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median survival of 27 months versus 11.2 months with standard treatment.
